ZAI LAB(ZLAB) - 2024 Q3 - Quarterly Report

Financial Performance - Net product revenue for Q3 2024 was $101.8 million, a 47$102.3 million, a 48% increase from $69.2 million in 2023, and for the nine months, revenues were$289.9 million, up 44% from $200.9 million[99]. - Product revenue increased by$32.6 million (47%) and $88.2 million (44$48.2 million, a 16% increase from $41.6 million in 2023, while VYVGART sales surged by 458$27.3 million[102]. - The company reported a net loss of $41.7 million for the three months ended September 30, 2024, a decrease from a net loss of$69.2 million in the same period of 2023[121]. - Net loss for the three months ended September 30, 2024, was $41.7 million, a 40$69.2 million in 2023, and for the nine months, the loss was $175.4 million, down 27$239.2 million[99]. Research and Development - The company anticipates continued significant investments in research and development to advance its pipeline of product candidates[93]. - ZL-1310, an investigational DLL3-antibody-drug conjugate, showed a 74% overall response rate in a Phase I study for extensive stage small cell lung cancer[83]. - KarXT demonstrated a statistically significant 9.2-point reduction in PANSS total score in a Phase III study for schizophrenia, with results expected to support a New Drug Application in early 2025[85]. - The company appointed Prista Charuworn, M.D., as Vice President of Immunology, Global R&D, to strengthen its R&D strategy[91]. - As of September 30, 2024, the company may incur up to $284.5 million in development and regulatory milestone payments for current clinical programs[97]. Expenses and Costs - Research and development expenses increased by$7.2 million (12%) for the three months ended September 30, 2024, primarily due to a $22.6 million increase in licensing fees[106]. - Cost of product revenue increased by$11.1 million (44%) and $34.8 million (49$1.3 million (2%) for the three months ended September 30, 2024, but increased by $17.1 million (9$17.1 million increase in selling, general, and administrative expenses for the nine months ended September 30, 2024[113]. Cash and Investments - The company had cash and cash equivalents of $716.1 million as of September 30, 2024, expected to meet cash requirements for at least the next 12 months[138]. - Net cash provided by financing activities was$112.1 million in the nine months ended September 30, 2024, compared to a net cash used of $6.8 million in the same period of 2023[144]. - The company had short-term debt of approximately$113.0 million related to new debt arrangements[140]. - The company held short-term investments of $16.3 million as of December 31, 2023, compared to nil as of September 30, 2024[154]. - Net cash used in operating activities decreased by$24.2 million in the nine months ended September 30, 2024, primarily due to a $63.8 million reduction in net loss[142]. Foreign Currency and Credit Risk - Foreign currency gains for the three months ended September 30, 2024, were$14.5 million, a 198% increase from $4.9 million in 2023[99]. - Interest income for the three months ended September 30, 2024, was$9.0 million, a slight decrease of 2% from $9.2 million in 2023[99]. - The company does not currently have significant direct foreign exchange risk, as its transactions are primarily settled in RMB[149]. - The value of the company's ADSs and ordinary shares is affected by the exchange rates between U.S. dollars, HK dollars, and RMB[151]. - The company manages credit risk related to accounts receivable through ongoing monitoring and has historically collected receivables within credit terms[156].